JP2004534763A - アミノグリコシド抗生物質の吸入投与のための方法および単位用量処方物 - Google Patents
アミノグリコシド抗生物質の吸入投与のための方法および単位用量処方物 Download PDFInfo
- Publication number
- JP2004534763A JP2004534763A JP2002590936A JP2002590936A JP2004534763A JP 2004534763 A JP2004534763 A JP 2004534763A JP 2002590936 A JP2002590936 A JP 2002590936A JP 2002590936 A JP2002590936 A JP 2002590936A JP 2004534763 A JP2004534763 A JP 2004534763A
- Authority
- JP
- Japan
- Prior art keywords
- tobi
- tobramycin
- dose
- treatment
- study
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000009472 formulation Methods 0.000 title claims abstract description 111
- 239000000203 mixture Substances 0.000 title claims abstract description 111
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 title claims abstract description 76
- 238000000034 method Methods 0.000 title claims description 39
- 239000000443 aerosol Substances 0.000 claims abstract description 95
- 229940126574 aminoglycoside antibiotic Drugs 0.000 claims abstract description 67
- 229930182566 Gentamicin Natural products 0.000 claims abstract description 6
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims abstract description 6
- 229960002518 gentamicin Drugs 0.000 claims abstract description 6
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims description 679
- 229960000707 tobramycin Drugs 0.000 claims description 677
- 238000011282 treatment Methods 0.000 claims description 300
- 229940126575 aminoglycoside Drugs 0.000 claims description 24
- 230000003115 biocidal effect Effects 0.000 claims description 9
- 239000003242 anti bacterial agent Substances 0.000 claims description 7
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 6
- 229930193140 Neomycin Natural products 0.000 claims description 3
- 229960004821 amikacin Drugs 0.000 claims description 3
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims description 3
- 229960000318 kanamycin Drugs 0.000 claims description 3
- 229930027917 kanamycin Natural products 0.000 claims description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 3
- 229930182823 kanamycin A Natural products 0.000 claims description 3
- 229960004927 neomycin Drugs 0.000 claims description 3
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 claims description 3
- 229960005322 streptomycin Drugs 0.000 claims description 3
- 238000012384 transportation and delivery Methods 0.000 abstract description 114
- 208000015181 infectious disease Diseases 0.000 abstract description 15
- 206010036790 Productive cough Diseases 0.000 description 154
- 208000024794 sputum Diseases 0.000 description 153
- 210000002966 serum Anatomy 0.000 description 151
- 210000003802 sputum Anatomy 0.000 description 151
- 102100032341 PCNA-interacting partner Human genes 0.000 description 135
- 101710196737 PCNA-interacting partner Proteins 0.000 description 135
- 239000006199 nebulizer Substances 0.000 description 125
- 208000009079 Bronchial Spasm Diseases 0.000 description 65
- 208000014181 Bronchial disease Diseases 0.000 description 65
- 206010006482 Bronchospasm Diseases 0.000 description 65
- 239000003814 drug Substances 0.000 description 62
- 229940079593 drug Drugs 0.000 description 61
- 210000004072 lung Anatomy 0.000 description 61
- 238000000151 deposition Methods 0.000 description 49
- 230000008021 deposition Effects 0.000 description 49
- 210000002700 urine Anatomy 0.000 description 47
- 230000000694 effects Effects 0.000 description 41
- 238000004458 analytical method Methods 0.000 description 40
- 239000000243 solution Substances 0.000 description 39
- 201000003883 Cystic fibrosis Diseases 0.000 description 35
- 238000002663 nebulization Methods 0.000 description 34
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 33
- 238000012360 testing method Methods 0.000 description 29
- 238000011084 recovery Methods 0.000 description 28
- 239000007921 spray Substances 0.000 description 28
- 230000008859 change Effects 0.000 description 25
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 24
- 238000012216 screening Methods 0.000 description 24
- 230000009467 reduction Effects 0.000 description 20
- 238000003556 assay Methods 0.000 description 17
- 238000011156 evaluation Methods 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 16
- 230000002485 urinary effect Effects 0.000 description 15
- 230000002411 adverse Effects 0.000 description 14
- 230000007423 decrease Effects 0.000 description 14
- 206010011224 Cough Diseases 0.000 description 13
- 210000003300 oropharynx Anatomy 0.000 description 13
- 229940109239 creatinine Drugs 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 230000008030 elimination Effects 0.000 description 10
- 238000003379 elimination reaction Methods 0.000 description 10
- 230000002093 peripheral effect Effects 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 241001227713 Chiron Species 0.000 description 9
- 230000002159 abnormal effect Effects 0.000 description 9
- 238000012387 aerosolization Methods 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 230000004199 lung function Effects 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 239000003708 ampul Substances 0.000 description 8
- 210000003238 esophagus Anatomy 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 238000011002 quantification Methods 0.000 description 8
- 230000004043 responsiveness Effects 0.000 description 8
- 238000013125 spirometry Methods 0.000 description 8
- 230000009885 systemic effect Effects 0.000 description 8
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 229940124630 bronchodilator Drugs 0.000 description 7
- 238000009533 lab test Methods 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 230000036470 plasma concentration Effects 0.000 description 7
- 230000002685 pulmonary effect Effects 0.000 description 7
- 238000003908 quality control method Methods 0.000 description 7
- 230000002285 radioactive effect Effects 0.000 description 7
- 230000029058 respiratory gaseous exchange Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 101150034459 Parpbp gene Proteins 0.000 description 6
- 238000000540 analysis of variance Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000000241 respiratory effect Effects 0.000 description 6
- 206010008479 Chest Pain Diseases 0.000 description 5
- 230000008369 airway response Effects 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000010606 normalization Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 231100000057 systemic toxicity Toxicity 0.000 description 5
- 229940101667 tobramycin 60 mg/ml Drugs 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 201000001474 proteinuria Diseases 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000000729 Fisher's exact test Methods 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 208000019693 Lung disease Diseases 0.000 description 3
- URWAJWIAIPFPJE-UHFFFAOYSA-N Rickamicin Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(CC=C(CN)O2)N)C(N)CC1N URWAJWIAIPFPJE-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000009325 pulmonary function Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- URWAJWIAIPFPJE-YFMIWBNJSA-N sisomycin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-YFMIWBNJSA-N 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000008227 sterile water for injection Substances 0.000 description 3
- 230000001839 systemic circulation Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 238000012935 Averaging Methods 0.000 description 2
- 238000000959 Cochran–Mantel–Haenszel (CMH) test Methods 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 206010033109 Ototoxicity Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 208000037656 Respiratory Sounds Diseases 0.000 description 2
- 208000036071 Rhinorrhea Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 206010047924 Wheezing Diseases 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000011545 laboratory measurement Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000007257 malfunction Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 231100000262 ototoxicity Toxicity 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000009522 phase III clinical trial Methods 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 238000012421 spiking Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000001521 two-tailed test Methods 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000864211 Cronartium quercuum Species 0.000 description 1
- 241000447938 Cyrtacanthacris tatarica Species 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 238000001347 McNemar's test Methods 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000032536 Pseudomonas Infections Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 231100000026 common toxicity Toxicity 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000011985 exploratory data analysis Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 208000000122 hyperventilation Diseases 0.000 description 1
- 230000000870 hyperventilation Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002171 loop diuretic Substances 0.000 description 1
- 230000005980 lung dysfunction Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052756 noble gas Inorganic materials 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000009613 pulmonary function test Methods 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 229910052713 technetium Inorganic materials 0.000 description 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 241001446247 uncultured actinomycete Species 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29223401P | 2001-05-18 | 2001-05-18 | |
| PCT/US2002/015999 WO2002094217A1 (en) | 2001-05-18 | 2002-05-17 | Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009185305A Division JP2009269923A (ja) | 2001-05-18 | 2009-08-07 | アミノグリコシド抗生物質の吸入投与のための方法および単位用量処方物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004534763A true JP2004534763A (ja) | 2004-11-18 |
| JP2004534763A5 JP2004534763A5 (https=) | 2006-01-05 |
Family
ID=23123791
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002590936A Pending JP2004534763A (ja) | 2001-05-18 | 2002-05-17 | アミノグリコシド抗生物質の吸入投与のための方法および単位用量処方物 |
| JP2009185305A Pending JP2009269923A (ja) | 2001-05-18 | 2009-08-07 | アミノグリコシド抗生物質の吸入投与のための方法および単位用量処方物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009185305A Pending JP2009269923A (ja) | 2001-05-18 | 2009-08-07 | アミノグリコシド抗生物質の吸入投与のための方法および単位用量処方物 |
Country Status (11)
| Country | Link |
|---|---|
| US (8) | US20030143162A1 (https=) |
| EP (2) | EP1320355B1 (https=) |
| JP (2) | JP2004534763A (https=) |
| AT (1) | ATE322249T1 (https=) |
| AU (1) | AU2010210026A1 (https=) |
| CA (1) | CA2447600C (https=) |
| DE (1) | DE60210402T2 (https=) |
| DK (1) | DK1320355T3 (https=) |
| ES (1) | ES2261735T3 (https=) |
| PT (1) | PT1320355E (https=) |
| WO (1) | WO2002094217A1 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009510077A (ja) * | 2005-09-29 | 2009-03-12 | ネクター セラピューティックス | 抗生物質製剤、単位用量、キットおよび方法 |
| JP2013530248A (ja) * | 2010-07-12 | 2013-07-25 | クセリア ファーマシューティカルズ エーピーエス | エアロゾル化によるトブラマイシンの投与による肺感染症の治療 |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW465235B (en) | 1998-09-17 | 2001-11-21 | United Video Properties Inc | Electronic program guide with digital storage |
| US20030143162A1 (en) | 2001-05-18 | 2003-07-31 | Speirs Robert John | Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics |
| US20040022740A1 (en) * | 2001-07-10 | 2004-02-05 | Baker William R. | Macrolide formulations for inhalation and methods of treatment of endobronchial infections |
| CA2456746A1 (en) * | 2001-08-20 | 2003-02-27 | Transave, Inc. | Method for treating lung cancers |
| PT1458360E (pt) | 2001-12-19 | 2011-07-13 | Novartis Ag | Derivados de indole como agonistas do recetor s1p1 |
| US8245708B2 (en) * | 2002-05-07 | 2012-08-21 | The Research Foundation Of State University Of New York | Methods, devices and formulations for targeted endobronchial therapy |
| US7607436B2 (en) * | 2002-05-06 | 2009-10-27 | The Research Foundation Of State University Of New York | Methods, devices and formulations for targeted endobronchial therapy |
| US9186322B2 (en) * | 2002-08-02 | 2015-11-17 | Insmed Incorporated | Platinum aggregates and process for producing the same |
| EP1545459A4 (en) * | 2002-08-02 | 2007-08-22 | Transave Inc | PLATINUM AGGREGATES, AND METHOD FOR MANUFACTURING THE SAME |
| AU2002953095A0 (en) * | 2002-11-29 | 2002-12-19 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
| EP1638549A4 (en) * | 2003-03-10 | 2011-06-15 | Optimer Pharmaceuticals Inc | NEW ANTIBACTERIAL AGENTS |
| NZ546821A (en) * | 2003-10-15 | 2009-04-30 | Pari Pharma Gmbh | Liquid preparation containing tobramycin |
| US20070065522A1 (en) * | 2004-03-18 | 2007-03-22 | Transave, Inc. | Administration of high potency platinum compound formulations by inhalation |
| CA2559722A1 (en) * | 2004-03-18 | 2005-09-29 | Transave, Inc. | Administration of cisplatin by inhalation |
| ES2388420T3 (es) * | 2004-05-17 | 2012-10-15 | Gilead Sciences, Inc. | Combinación de fosfomicina/aminoglucósido aerosolizada para el tratamiento de las infecciones respiratorias bacterianas |
| WO2005112957A1 (en) * | 2004-05-21 | 2005-12-01 | Transave, Inc. | Treatment of lung diseases and pre-lung disease conditions |
| WO2006002178A1 (en) | 2004-06-18 | 2006-01-05 | Novartis Vaccines And Diagnostics Inc. | Methods of treatment of endobronchial infections |
| MX2007004955A (es) * | 2004-11-08 | 2007-06-14 | Transave Inc | Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente. |
| AU2013206401B2 (en) * | 2005-09-29 | 2016-06-23 | Novartis Ag | Antibiotic formulations, unit doses, kits, and methods |
| US9107824B2 (en) | 2005-11-08 | 2015-08-18 | Insmed Incorporated | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
| WO2007056263A2 (en) * | 2005-11-08 | 2007-05-18 | Transave, Inc. | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously |
| US20070190182A1 (en) * | 2005-11-08 | 2007-08-16 | Pilkiewicz Frank G | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
| US20070190181A1 (en) * | 2005-11-08 | 2007-08-16 | Pilkiewicz Frank G | Methods of treating cancer with lipid-based platinum compound forumulations administered intravenously |
| WO2007064658A2 (en) * | 2005-11-30 | 2007-06-07 | Transave, Inc. | Safe and effective methods of administering therapeutic agents |
| EP3067047B1 (en) | 2005-12-08 | 2022-04-20 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections |
| US8337814B2 (en) * | 2005-12-15 | 2012-12-25 | Topical Sinus Therapeutics, Inc. | Treatment of active infections, sinusitis, rhinitis, and related neurological disorders and related compositions |
| JP2008199905A (ja) * | 2007-02-16 | 2008-09-04 | Snow Brand Milk Prod Co Ltd | 乳酸菌生残性向上剤 |
| EP2214484A4 (en) | 2007-10-25 | 2013-01-02 | Cempra Pharmaceuticals Inc | PROCESS FOR PREPARING ANTIBACTERIAL MAKROLIDE AGENTS |
| CN101981688B (zh) * | 2008-04-02 | 2014-04-02 | Imec公司 | 制造半导体器件的方法以及半导体器件 |
| JP5711135B2 (ja) | 2008-10-24 | 2015-04-30 | センプラ ファーマシューティカルズ，インコーポレイテッド | 胃腸疾患を治療するための方法 |
| US9937194B1 (en) | 2009-06-12 | 2018-04-10 | Cempra Pharmaceuticals, Inc. | Compounds and methods for treating inflammatory diseases |
| ES2608285T3 (es) | 2009-09-10 | 2017-04-07 | Cempra Pharmaceuticals, Inc. | Procedimientos para el tratamiento de paludismo, tuberculosis y enfermedades por MAC |
| MX361413B (es) | 2010-03-22 | 2018-12-05 | Cempra Pharmaceuticals Inc Star | Formas cristalinas de un macrólido y usos para las mismas. |
| CN102917708B (zh) | 2010-05-20 | 2015-11-25 | 森普拉制药公司 | 制备大环内酯和酮内酯及其中间体的方法 |
| EP2613630A4 (en) | 2010-09-10 | 2014-01-15 | Cempra Pharmaceuticals Inc | HYDROGEN BOND FOR THE PREPARATION OF FLUOROCHETOLIDES FOR THE TREATMENT OF DISEASES |
| US8826904B2 (en) | 2011-07-12 | 2014-09-09 | Cardeas Pharma Corporation | Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis |
| KR20140025534A (ko) | 2011-07-12 | 2014-03-04 | 카르데아스 파마 인코퍼레이티드 | 아미카신과 포스포마이신 조합물의 제형 및 인공호흡기 관련 폐렴(vap)과 인공호흡기 관련 기도(vat) 기관지염의 치료 방법 및 시스템 |
| NZ700182A (en) | 2012-03-27 | 2017-02-24 | Cempra Pharmaceuticals Inc | Parenteral formulations for administering macrolide antibiotics |
| GB201208080D0 (en) | 2012-05-09 | 2012-06-20 | Norton Healthcare Ltd | Tobramycin formulation |
| DK2892524T3 (da) | 2012-09-04 | 2021-01-25 | Eleison Pharmaceuticals LLC | Forebyggelse af pulmonalt kræfttilbagefald med lipid-komplekseret cisplatin |
| US10124066B2 (en) | 2012-11-29 | 2018-11-13 | Insmed Incorporated | Stabilized vancomycin formulations |
| EP2943503B1 (en) | 2013-01-11 | 2017-08-23 | Xellia Pharmaceuticals ApS | Polymyxins, compositions, methods of making and methods of use |
| AU2014239959A1 (en) * | 2013-03-14 | 2015-10-01 | Cempra Pharmaceuticals, Inc. | Methods for treating respiratory diseases and formulations therefor |
| CN105188712A (zh) | 2013-03-15 | 2015-12-23 | 森普拉制药公司 | 用于制备大环内酯抗菌剂的收敛方法 |
| LT3466432T (lt) | 2014-05-15 | 2020-12-28 | Insmed Incorporated | Būdai, skirti plaučių netuberkuliozinėms mikobakterinėms infekcijoms gydyti |
| EP3166960B1 (en) | 2014-07-09 | 2019-08-07 | Xellia Pharmaceuticals ApS | Low substituted polymyxins and compositions thereof |
| US10532080B2 (en) | 2014-10-03 | 2020-01-14 | Xellia Pharmaceuticals Aps | Sulfomethylated polymixin compositions |
| JP6626890B2 (ja) | 2014-10-03 | 2019-12-25 | クセリア ファーマシューティカルズ エーピーエスＸｅｌｌｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ ＡｐＳ | 吸入用デバイスおよび同デバイスに含有される水溶液 |
| US10617703B2 (en) | 2014-12-10 | 2020-04-14 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
| US11793783B2 (en) | 2015-08-05 | 2023-10-24 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
| US10898491B2 (en) | 2015-12-18 | 2021-01-26 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
| US11690815B2 (en) | 2015-08-05 | 2023-07-04 | Cmpd Licensing Llc | Hyperkeratotic skin condition treatments and compositions |
| US11684567B2 (en) | 2015-08-05 | 2023-06-27 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
| US11278590B2 (en) | 2015-08-05 | 2022-03-22 | Cmpd Licensing, Llc | Compositions and methods for treating nail infections |
| US10898455B2 (en) | 2016-01-07 | 2021-01-26 | Cmpd Licensing, Llc | Urea cream formulations |
| US11446236B2 (en) | 2015-08-05 | 2022-09-20 | Cmpd Licensing, Llc | Topical antimicrobial compositions and methods of formulating the same |
| US9999604B2 (en) | 2016-11-17 | 2018-06-19 | Cmpd Licensing, Llc | Compounded solutions of diclofenac and lidocaine and methods |
| US10525025B2 (en) | 2016-11-17 | 2020-01-07 | Cmpd Licensing, Llc | Compounded compositions and methods for treating pain |
| EP3773505B1 (en) | 2018-03-30 | 2026-04-29 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
| JP7449275B2 (ja) | 2018-05-02 | 2024-03-13 | インスメッド インコーポレイテッド | リポソーム薬物製剤の製造方法 |
| WO2020163416A1 (en) * | 2019-02-05 | 2020-08-13 | Mylan Inc | Devices and methods for tobramycin inhalation treatment |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09511254A (ja) * | 1994-10-19 | 1997-11-11 | パソジェネシス コーポレイション | エアゾル化のための新規および改良されたアミノグリコシド処方物 |
| JPH10508251A (ja) * | 1995-08-31 | 1998-08-18 | フルイド・プロパルション・テクノロジーズ，インコーポレイテッド | 液体分配装置および方法 |
| WO1998043650A1 (en) * | 1997-04-02 | 1998-10-08 | Pathogenesis Corporation | A method and a tobramycin aerosol formulation for treatment, prevention and containment of tuberculosis |
| WO2000035461A1 (en) * | 1998-12-17 | 2000-06-22 | Pathogenesis Corporation | Method for the treatment of severe chronic bronchitis (bronchiectasis) with an aerosolized antibiotic |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3993223A (en) | 1974-07-25 | 1976-11-23 | American Home Products Corporation | Dispensing container |
| US4502616A (en) | 1982-01-04 | 1985-03-05 | Health Care Concepts, Inc. | Single use vial |
| GB8801655D0 (en) | 1988-01-26 | 1988-02-24 | Waverley Pharma Ltd | Ampoules |
| ES2038445T3 (es) | 1988-01-28 | 1993-07-16 | Lameplast S.R.L. | Tiras de ampollas para productos farmaceuticos, cosmeticos y otros. |
| GB8802349D0 (en) | 1988-02-03 | 1988-03-02 | Waverley Pharma Ltd | Ampoule with luer |
| DE3916840A1 (de) | 1988-09-21 | 1990-03-29 | Bernd Hansen | Ampulle |
| US5409125A (en) | 1989-12-11 | 1995-04-25 | Aktiebolaget Astra | Unit dose container |
| CA2027690A1 (en) | 1990-10-18 | 1992-04-19 | Christian Laing | Plastic ampul |
| FR2687066A1 (fr) | 1992-02-06 | 1993-08-13 | Oreal | Ampoule autocassable. |
| SE9902627D0 (sv) * | 1999-07-08 | 1999-07-08 | Siemens Elema Ab | Medical nebulizer |
| DE19953317C1 (de) | 1999-11-05 | 2001-02-01 | Pari Gmbh | Inhalationsvernebler |
| US20030143162A1 (en) | 2001-05-18 | 2003-07-31 | Speirs Robert John | Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics |
-
2002
- 2002-05-17 US US10/151,701 patent/US20030143162A1/en not_active Abandoned
- 2002-05-17 PT PT02771857T patent/PT1320355E/pt unknown
- 2002-05-17 DK DK02771857T patent/DK1320355T3/da active
- 2002-05-17 ES ES02771857T patent/ES2261735T3/es not_active Expired - Lifetime
- 2002-05-17 WO PCT/US2002/015999 patent/WO2002094217A1/en not_active Ceased
- 2002-05-17 EP EP02771857A patent/EP1320355B1/en not_active Revoked
- 2002-05-17 CA CA2447600A patent/CA2447600C/en not_active Expired - Fee Related
- 2002-05-17 DE DE60210402T patent/DE60210402T2/de not_active Revoked
- 2002-05-17 JP JP2002590936A patent/JP2004534763A/ja active Pending
- 2002-05-17 EP EP09015943A patent/EP2186508A3/en not_active Withdrawn
- 2002-05-17 AT AT02771857T patent/ATE322249T1/de active
-
2003
- 2003-12-22 US US10/743,529 patent/US6890907B2/en not_active Expired - Lifetime
-
2004
- 2004-07-01 US US10/883,143 patent/US20040265241A1/en not_active Abandoned
-
2005
- 2005-05-10 US US11/125,670 patent/US20050207987A1/en not_active Abandoned
- 2005-05-10 US US11/126,108 patent/US20050201947A1/en not_active Abandoned
-
2007
- 2007-10-24 US US11/923,486 patent/US7825095B2/en not_active Expired - Lifetime
-
2009
- 2009-08-07 JP JP2009185305A patent/JP2009269923A/ja active Pending
-
2010
- 2010-08-09 AU AU2010210026A patent/AU2010210026A1/en not_active Abandoned
- 2010-09-17 US US12/884,505 patent/US20110005518A1/en not_active Abandoned
-
2011
- 2011-11-14 US US13/295,228 patent/US8507454B2/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09511254A (ja) * | 1994-10-19 | 1997-11-11 | パソジェネシス コーポレイション | エアゾル化のための新規および改良されたアミノグリコシド処方物 |
| JPH10508251A (ja) * | 1995-08-31 | 1998-08-18 | フルイド・プロパルション・テクノロジーズ，インコーポレイテッド | 液体分配装置および方法 |
| WO1998043650A1 (en) * | 1997-04-02 | 1998-10-08 | Pathogenesis Corporation | A method and a tobramycin aerosol formulation for treatment, prevention and containment of tuberculosis |
| WO2000035461A1 (en) * | 1998-12-17 | 2000-06-22 | Pathogenesis Corporation | Method for the treatment of severe chronic bronchitis (bronchiectasis) with an aerosolized antibiotic |
Non-Patent Citations (6)
| Title |
|---|
| JPN6010052242, Ｊｏｕｒｎａｌ ｏｆ ａｅｒｏｓｏｌ ｍｅｄｉｃｉｎｅ, １９９９， Ｖｏｌ．１２， Ｓｕｐｐｌ． １, ｐａｇｅｓ Ｓ９−Ｓ１７ * |
| JPN7009001807, Ａｍｅｒｉｃａｎ ｒｅｖｉｅｗ ｏｆ ｒｅｓｐｉｒａｔｏｒｙ ｄｉｓｅａｓｅ, １９９３， Ｖｏｌ．１４７， Ｎｏ．５, ｐａｇｅｓ １２７９−１２８２ * |
| JPN7009001808, Ｒｅｓｐｉｒａｔｏｒｙ ｄｒｕｇ ｄｅｌｉｖｅｒｙ ＶＩ, １９９８, ｐａｇｅｓ ９１−９５ * |
| JPN7009001809, Ｒｅｖｕｅ ｄｅｓ ｍａｌａｄｉｅｓ ｒｅｓｐｉｒａｔｏｉｒｅｓ, １９９６， Ｖｏｌ．１３， Ｎｏ．２, ｐａｇｅｓ １５５−１６２ * |
| JPN7009001813, ｐｒｅｓｓ ｒｅｌｅａｓｅ ｂｙ ＰａｔｈｏＧｅｎｅｓｉｓ ｃｏｒｐｏｒａｔｉｏｎ, Ｊｕｌｙ １１ｓｔ ２０００ * |
| JPN7010002844, Ｒｅｓｐｉｒａｔｏｒｙ ｄｒｕｇ ｄｅｌｉｖｅｒｙ ＶＩＩ, ２０００, ｐａｇｅｓ ３０７−３０９ * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009510077A (ja) * | 2005-09-29 | 2009-03-12 | ネクター セラピューティックス | 抗生物質製剤、単位用量、キットおよび方法 |
| JP2013530248A (ja) * | 2010-07-12 | 2013-07-25 | クセリア ファーマシューティカルズ エーピーエス | エアロゾル化によるトブラマイシンの投与による肺感染症の治療 |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE322249T1 (de) | 2006-04-15 |
| DE60210402T2 (de) | 2006-12-07 |
| US7825095B2 (en) | 2010-11-02 |
| EP1320355A1 (en) | 2003-06-25 |
| US6890907B2 (en) | 2005-05-10 |
| EP2186508A2 (en) | 2010-05-19 |
| US8507454B2 (en) | 2013-08-13 |
| US20110005518A1 (en) | 2011-01-13 |
| US20120101055A1 (en) | 2012-04-26 |
| US20040131555A1 (en) | 2004-07-08 |
| PT1320355E (pt) | 2006-08-31 |
| US20050201947A1 (en) | 2005-09-15 |
| CA2447600A1 (en) | 2002-11-28 |
| WO2002094217A1 (en) | 2002-11-28 |
| EP1320355B1 (en) | 2006-04-05 |
| DK1320355T3 (da) | 2006-07-31 |
| EP2186508A3 (en) | 2010-08-25 |
| DE60210402D1 (de) | 2006-05-18 |
| JP2009269923A (ja) | 2009-11-19 |
| US20050207987A1 (en) | 2005-09-22 |
| US20040265241A1 (en) | 2004-12-30 |
| US20030143162A1 (en) | 2003-07-31 |
| AU2010210026A1 (en) | 2010-09-02 |
| ES2261735T3 (es) | 2006-11-16 |
| US20080095717A1 (en) | 2008-04-24 |
| CA2447600C (en) | 2015-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004534763A (ja) | アミノグリコシド抗生物質の吸入投与のための方法および単位用量処方物 | |
| EP1765288B1 (en) | Tobramycin formualtions for treatment of endobronchial infections | |
| Geller et al. | Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system | |
| KR102012418B1 (ko) | 에어로졸화에 의한 토브라마이신의 투여에 의한 폐 감염의 치료 | |
| Rodrigo et al. | Salbutamol treatment of acute severe asthma in the ED: MDI versus hand-held nebulizer | |
| Noone et al. | Airway deposition and clearance and systemic pharmacokinetics of amiloride following aerosolization with an ultrasonic nebulizer to normal airways | |
| AU2007202942B2 (en) | Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics | |
| O'Doherty et al. | Nebuliser therapy in the intensive care unit | |
| EP1598059A1 (en) | Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics | |
| Trnovec et al. | Pharmacokinetics of gentamicin administered intratracheally or as an inhalation aerosol to guinea pigs. | |
| Gibson et al. | Drug delivery in asthma: a comparison of spacers with a jet nebuliser | |
| US20030140920A1 (en) | Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma | |
| AU2002339338A1 (en) | Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics | |
| CN101951906A (zh) | 用于治疗肺病中的健康相关生命质量缺陷的吸入式氨曲南赖氨酸 | |
| Asmus et al. | Tobramycin as a pharmacologic tracer to compare airway deposition from nebulizers | |
| Quezada et al. | Effect of different inhaled bronchodilators on recovery from methacholine‐induced bronchoconstriction in asthmatic children | |
| Vecellio et al. | Pharmacokinetics of high-dose nebulized amikacin in mechanically ventilated healthy | |
| Newhouse et al. | USE OF AN ENGINEERED DRY POWDER AEROSOL (PULMOSPHERE™) FOR IMPROVED EFFICIENCY AND REPRODUCIBILITY OF LARGE UNIT DOSE TOBRAMYCIN BY DPI IN HEALTHY VOLUNTEERS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050516 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050516 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090409 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090703 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090710 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090807 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090807 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100913 |